Cancer Treatment Reviews
Volume 37, Issue 3 , Pages 178-184 , May 2011

Sunitinib for the treatment of metastatic renal cell carcinoma

  • Stéphane Oudard

      Affiliations

    • Oncology Department, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 6 25 16 21 60, +33 1 56 09 34 47 (Secrétaire), +33 1 56 09 34 74 (Bureau); fax: +33 1 56 09 24 31.
    • ,
  • Benoit Beuselinck

      Affiliations

    • Oncology Department, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France
    • ,
  • Jasper Decoene

      Affiliations

    • Department of Urology, University of Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany
    • ,
  • Peter Albers

      Affiliations

    • Department of Urology, University of Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany

Received 4 June 2010 ,Revised 26 July 2010 ,Accepted 8 August 2010.

References 

  1. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;PM:15674877.
  2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–3590
  3. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus Interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144–2150
  4. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137–2143
  5. Pfizer Inc. SUTENT, summary of product characteristics, October 2009.
  6. Ljungberg B, Cowan N, Hanbury DC et al. Guidelines on renal cell carcinoma, 2010. <http://www.uroweb.org/?id=218&gid=4>.
  7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer v.2. 2010.
  8. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel–Lindau tumor suppressor protein. J Biol Chem. 2000;275:25733–25741
  9. Kaelin WG. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004;10:6290S–6295S
  10. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991–5004
  11. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–187
  12. Oudard S, George D, Medioni J, Motzer R. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol. 2007;18(Suppl. 10):x25–x31
  13. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003;2:1011–1021
  14. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–337
  15. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20:757–766
  16. O’Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597–3605
  17. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006;91:4070–4076
  18. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1027
  19. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692–1703
  20. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27:4068–4075
  21. Sakamoto JM. SU-11248 Sugen. Curr Opin Investig Drugs. 2004;5:1329–1339
  22. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2009. doi: 10.1007/s00280-009-1170-y [E-pub ahead of print].
  23. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24
  24. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007;178:1883–1887
  25. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  26. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib with subpopulation analysis in an expanded-access trial of metastatic renal cell carcinoma. Lancet Oncol. 2009;10:757–763
  27. Rosenberg JE, Motzer RJ, Michaelson MD. Sunitinib therapy for patients with metastatic renal cell carcinoma (mRCC): updated results of two phase II trials and prognostic factor analysis for survival. J Clin Oncol 2007; ASCO annual meeting proceedings part I. 25(18S) (June 20 Suppl.) (Abstract 5095).
  28. Motzer RJ, Michaelson MD, Hutson TE, et al. Sunitinib versus interferon-alfa (IFN-á) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors (abstract). In: Poster presentation at: the 14th European cancer conference, Barcelona, Spain, September 23–27, 2007.
  29. Porta C, Szczylik C, Bracarda S, et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. J Clin Oncol. 2008;26:[abstract 5114]
  30. Cella D, Li JZ, Cappelleri JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008;26:3763–3769
  31. Munir U, Benedict Á, Borgman B et al. Cost-effectiveness of sunitinib vs sorafenib, temsirolimus and bevacizumab+interferon-alfa first-line therapy for metastatic renal cell carcinoma - adaptation for the Swedish Health Service. In: Poster presented at the 33rd European society of medical oncology congress, Stockholm, Sweden, 12–16, September 2008 [abstract 725P].
  32. Benedict Á, Charbonneau C, Kim ST, Négrier S. Cost-effectiveness of sunitinib (SU), sorafenib (SFN), temsirolimus (TMS), and bevacizumab plus interferon-alfa (BEV/IFN) as 1st-line therapy for metastatic renal cell carcinoma (mRCC) – an indirect comparison. In: Poster presented at the 33rd European society for medical oncology congress, Stockholm, Sweden, 12–16 September, 2008 [Abstract 723P].
  33. Diaz S, Calvo Aller E, Maroto P et al. Cost-effectiveness and cost-utility analysis of sunitinib vs sorafenib and bevacizumab+interferon-alfa as first-line treatment for metastatic renal cell carcinoma in Spain. In: Poster presented at the 33rd European society of medical oncology congress, Stockholm, Sweden, 12–16 September, 2008 [Abstract 724P].
  34. National Institute for Health and Clinical Excellence. Final appraisal determination – sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. 2004.
  35. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358:95–97
  36. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J. 2007;1:S41–S54
  37. Di LG, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20:1535–1542
  38. Schmidinger M, Bojic A, Vogl UM, Lamm W, Zielinski CC. Management of cardiac adverse events occurring with sunitinib treatment. Anticancer Res. 2009;29:1627–1629
  39. Szczylik C, Porta C, Bracarda S, et al. Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26(May 20 Suppl.) [abstract 5124].
  40. Hariharan S, Szczylik C, Porta C, et al. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial. J Clin Oncol. 2008;26:(abstract 5094; poster presentation)
  41. Negrier S, Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer Suppl. 2007;5:12–19
  42. Ravaud A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol. 2009;20(Suppl. 1):i7–i12
  43. Roigas J. Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma. Eur Urol Suppl. 2008;7:593–600
  44. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53:917–930
  45. Medioni J, Choueiri TK, Zinzindohoue F, Cho D, Fournier L, Oudard S. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. J Urol. 2009;181:2470–2475
  46. Cooney MM, Garcia JA, Elson P, et al. Sunitinib and bevacizumab in advanced solid tumors: a phase I trial (Abstract). In: Poster presented at the 44th annual meeting of the American society of clinical oncology, Chicago, Illinois, 30 May–3 June, 2008 [Abstract 3530].
  47. Feldman DR, Ginsberg MS, Baum M et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. In: Poster presented at the 44th annual meeting of the American society of clinical oncology, Chicago, Illinois, 30 May–3 June, 2008.
  48. Medioni J, Banu E, Helley D, et al. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. Eur Urol 2009.
  49. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009;7:24–27
  50. Oudard S, Medioni J, Aylllon J, et al. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2009;9:705–717
  51. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–456
  52. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281
  53. <http://www.clinicaltrials.gov>.
  54. <http://www.cancer.gov/clinicaltrials/EORTC-30073>.

PII: S0305-7372(10)00140-4

doi: 10.1016/j.ctrv.2010.08.005

Cancer Treatment Reviews
Volume 37, Issue 3 , Pages 178-184 , May 2011

Article Tools

* Image Usage & Resolution